杨

杨静 (Jing Yang)

ShanghaiTech University研究员

H指数:18

被引数:2,276

个人简介

"2009年毕业于山东大学，获理学学士；2015年毕业于中国科学院上海免疫与感染研究所，获理学博士。博士阶段主要鉴定了一系列靶向自身免疫病、炎症、肿瘤等疾病状态下致病蛋白的促降解新靶点DUB/E3并深入探索阐明了作用机制。\n2015年-2020年底在美国哈佛大学医学院Dana-Farber癌症研究所Sara J. Buhrlage和James D. Griffin教授实验室进行博士后训练，2021年1月-2022年8月在中国科学院合肥研究院任副研究员，开展了多种恶性血液肿瘤的治疗型新靶点DUB/E3 发现和首创型降解剂研发。\n2022年9月加盟同济大学生命科学与技术学院，入选上海市“高层次人才引进计划”，任特聘研究员，博士生导师。2023年1月至今兼任上海市同济医院研究员。部分成果以第一或通讯（含共同）作者在Nat. Chem. Biol.，Nat. Commun., Advanced Science（2025a, 2025b），Leukemia（2022a，2022b），Signal Trans. Target. Ther.,等重要学术期刊发表研究论文20余篇，受到Nat. Rev. Drug Discov., Nat. Immunol.等国际期刊亮点专评，成果转化已公布/实审专利6项（授权2项）。受邀参编英文专著一部（ISSN 2213-2775），担任Front. cell. infect. Microbiol., Front. Immunol.客座编辑，J.Med.Chem., Eur. J. Immunol. 等国际期刊审稿专家，中国细胞生物学学会、中国免疫学会会员等，并多次在国际国内学术会议做大会及分会报告。主持国家自然科学基金2项，中国科学院青年创新促进会会员和安徽省“百人计划”青年项目，参与国自然重点研发项目等。\n研究内容\n当前针对临床开发的传统抑制剂等药物，常通过口袋占位、竞争性结合靶底物等起作用。但长期用药易导致多机制耐药（如二次突变，代偿效应和旁路效应等），对突变致病蛋白易脱靶野生型产生安全性问题，且仍有80%的致病蛋白难以开发成药，原因复杂多样，如：蛋白本身缺乏结合腔、定位核内药物无法抵达、致病机制不依赖酶活或通过蛋白间相互作用（PPI）等。靶向蛋白质降解技术（Targeted Protein Degradation）是近年来出现的最有望打破这一系列瓶颈的新策略，是创新药物研究领域的热点和前沿。基于泛素连接酶（Ubiquitin ligase E3）或去泛素化酶（Deubiquitinase, DUB）的降解剂既能突破传统占位抑制小分子的局限，无需竞争性结合位点，又具有低剂量低毒性的优势，尤其是能克服多机制耐药性和 “非成药”靶点等，因此越来越受到业界和学界的重视，有望成为对抗耐药和“非成药”靶点的新武器。但面临传统化学遗传学筛选体系的缺陷造成的靶点筛选困难，和仅有少数E3连接酶或DUB及其配体能用于开发和应用这两大挑战。\n本课题组基于多样化高通量筛选系统，综合运用分子生物学、生化与细胞生物学、化学合成学、结合计算机模拟和生物信息学等手段，开发针对特定致病蛋白的降解剂高通量高效筛选平台，围绕促降解新靶点DUB/E3及其配体的开发两方面，结合临床需求，研发高活性、高选择性降解剂，进而开发原创型临床候选药物，为血液肿瘤等恶性疾病的治疗提供新策略。\n本课题组常年招聘博士后，欢迎博士生、硕士生、本科生报考和实习。\n代表性工作\n1. Guiming Li#, Jun Wang#, Shiguang Ye#, Lixin Zhou, Yanli Sun, Bowen Li, Yunshuo Zhao, Yi Ding, Yu Zeng, Bin Xue, Guangming Wang, Fangce Wang, Xiu Luo, Aibin Liang, Ellen L. Weisberg, Wenjun Zhang*, Wenchao Lu*, Jing Yang*. Arsenic Trioxide Promotes a Glue‑like Interaction to Drive STUB1-Mediated NPM-ALK Degradation in ALK⁺ ALCL. Experimental Hematology & Oncology. Jun. 2026\n2. Bowen Li#, Haoran Xu#, Wenjun Zhang, Jing Yang*. Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy. Molecular Therapy Oncology. May 2026, 34, 201232\n3.Mingqi Hou#; Wenjun Zhang#; Ziping Qi#; Guiming Li#; Husheng Mei; Shuang Qi; Rui Jin; Yuedong Zhao; Xiaochen Tang; Bing Xiu; Xiaotong Chen; Yunshuo Zhao; Chen Hu; Changlin Qian; Xiuchun Li; Zhan Xu; Yongfei Chen; Chao Wu; Beilei Wang; Lejin Yan; Dan Li; Yushan Huang; Rui Liang; Aoli Wang; Jing Liu; Wenchao Wang; Bin Li; Jun Long; Ping Li; Aibin Liang*; Qingsong Liu*; Jing Yang*. Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs. Nature Communications. Mar. 2026, 17, 3045.\n4. Yajing Yang#, Bowen Li#, Jing Yang*. Therapeutic Targets and Strategies for Long COVID and Post-Viral Syndrome. Frontiers in Cellular and Infection Microbiology. Mar. 2026;16, 1820002\n5. Yushan Huang#, Jun Long#, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian*, Jing Yang*, Aibin Liang*. Overcoming Challenges in CAR-T Therapy for Malignancies: Mechanisms and Strategies. Clinical and Translational Discovery. Feb. 2026;6:e70045.\n6. Husheng Mei#, Wuqiang Wen#, Wenjun Zhang#, Shujing Zhang#, Ting Sun#, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao*, Aibin Liang*, Baishan Jiang*, Jing Yang*. Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. Advanced Science. Dec. 2025, 13(7): e15127.\n7. Linhui Cao#, Jing Yang#, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Huang, Yanli Sun, Lixin Zhou, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Lu, Kehao Zhao*, Wenchao Lu*. Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity. Advanced Science. Dec. 2025, 12(48): e03277.\n8. Sun, Yanli#; Zhang, Fengying#; Zhou, Lixin#; Feng, Yixuan; Huang, Lu; Lu, Qiuxian; Yuan, Xin; Hou, Wenqing; Liu, Biwei; Guo, Zhixiang; Chen, Lu; Peng, Bo; Yin, Xianzhen; Zhang, Yiwen; Yang, Jing*; Chen, Nan*; Lu, Wenchao*. Discovery of Potent, Allosteric GSTO1 Covalent Inhibitors with a New Binding Mode. Journal of Medicinal Chemistry. Nov. 2025, 68(22): 24075-24093\n9. Yiying Xue#, Bing Xiu#, Muye Yang#, Yanwei Zhang#, Changpeng Yang, Lele Zhang, Yilv Yan, Xiu Luo, Yushan Huang, Husheng Mei, Guiming Li, Lixin Zhou, Yisa Chen, Wenjun Zhang, Changlin Qian, Peng Zhang, Juan Liu*, Aibin Liang*, Yu Zeng*, Jing Yang*. Ubiquitin-Specific Protease 7-Mediated Stabilization of Discoidin Domain Receptor 1 Drives Progression of TP53-Mutant Cancers. Journal of Biological Chemistry. 2025 Sep;301(9):110515.\n10. Guiming Li#, Wenjun Zhang*, Jing Yang*. Time - the fourth dimension of immune cells. MedComm. 2024 Aug 4;5(8):e682.\n11. Yiying Xue#, Husheng Mei#, Yisa Chen, James D. Griffin, Qingsong Liu*, Ellen Weisberg*, Jing Yang*. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2. MedComm. 2023 May 14;4(3):e254.\n12. Yisa Chen, Yiying Xue, Jing Yang*. Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19. Journal of Medical Virology, 2023 Mar; 95(3):e28592.\n13. Husheng Mei#, Hong Wu#, Jing Yang#, Bin Zhou#, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang*, Jing Liu*, Qingsong Liu*. Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer. Signal Transduct. Target Ther., 8 (1), 18, Jan. 2023.\n14. Jing Yang#, Ellen L. Weisberg#, Shuang Qi#, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage*, Qingsong Liu*, James D. Griffin*. "